A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide )
Patients with Peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot
be treated successfully with the conventional chemotherapy of CHOP. The investigators have
been proceeding this trial to evaluate the efficacy and safety of the combination
chemotherapy regiment GDPT regiment (gemcitabine,cisplatin,Prednisone ,Thalidomide
) in the patients with Peripheral T-cell lymphoma.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival
up to end of follow-up-phase (approximately 24 months)
No
Mingzhi Zhang, Pro,Dr
Principal Investigator
The First Affiliated Hospital of Zhengzhou University
China: Food and Drug Administration
hnslblzlzx2011-3
NCT01664975
August 2011
December 2019
Name | Location |
---|